Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study.

View Full Paper
Ask AI
Bookmark
Share

Authors

BDBarbara DuplaixCGCamille GolfierSCStéphanie Cordeil

Discussion

Loading...

Member takes

Overview

Retrospective analysis reports 51% overall response rate in relapsed myeloma patients, indicating favorable safety profile of carfilzomib combinations.

Key Points

  • Overall response rate reached 51%, with notable instances of peripheral neuropathy being lower compared to other treatments.
  • In this cohort, median overall survival was observed at 16.6 months, highlighting possible benefits of carfilzomib treatment.
  • Safety assessment indicated hypertension as the most frequent adverse event, with few cases of thrombotic microangiopathy reported.
  • Favorable outcomes suggest that carfilzomib-based treatments could be viable options for managing relapsed multiple myeloma.

Cite This Study

Duplaix et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4eahttps://doi.org/10.1182/blood-2025-7530
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical efficacy and safety of daratumumab-carfilzomib based therapy in newly diagnosed multiple myeloma: A retrospective cohort analysis2025
  2. 2Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study2025
  3. 3Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study2025
  4. 4[Analysis of the efficacy of a carfilzomib-based regimen in the treatment of relapsed and refractory multiple myeloma].2025
  5. 5A real-world study on first-line early switch to kpd regimen in the treatment of multiple myeloma patients with suboptimal induction efficacy or intolerance2025